MD
MDWD.US Mediwound Ltd
- Market cap
- USD 186M
- P/E
- -
- P/B
- 5.20x
- ROE
- -68.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is MDWD.US undervalued?
Graham numberThe Graham number of Mediwound Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Mediwound Ltd fundamental analysis
No fundamental analysis for Mediwound Ltd yet.
Mediwound Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Mediwound Ltd
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bio…
Full company profileMediwound Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Mediwound Ltd annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.56M | 2.50M | 3.40M | 31.8M | 21.8M | 23.8M | 26.5M | 18.7M | 20.2M | 17.0M | 10.9M |
| Gross Profit | -600K | 918K | 1.31M | 19.9M | 7.55M | 8.77M | 13.2M | 3.58M | 2.63M | 3.25M | 2.24M |
| Operating Income | -20.2M | -13.7M | -3.96M | 4.49M | -8.84M | -11.2M | -7.66M | -15.5M | -19.4M | -25.3M | -34.6M |
| EBITDA | -17.4M | -13.1M | -4.20M | 4.14M | -7.35M | -11.4M | -18.2M | -4.80M | -27.9M | -21.5M | -26.4M |
| Net Income | -18.9M | -22.1M | -1.06M | 4.96M | -9.20M | -13.6M | -19.6M | -6.72M | -30.2M | -23.9M | -21.8M |
| EPS | -6.05 | -6.64 | -0.27 | 1.28 | -2.37 | -3.48 | -3.93 | -0.75 | -3.03 | -2.10 | -1.67 |
| Balance Sheet | |||||||||||
| Total Assets | 35.8M | 44.1M | 35.3M | 40.6M | 31.1M | 19.7M | 50.0M | 66.5M | 73.5M | 86.3M | 65.5M |
| Total Liabilities | 28.0M | 34.5M | 26.3M | 25.4M | 23.8M | 24.3M | 39.1M | 34.9M | 42.3M | 42.6M | 33.7M |
| Shareholders' Equity | 7.77M | 9.62M | 8.97M | 15.2M | 7.27M | -4.58M | 10.9M | 31.6M | 31.2M | 43.6M | 31.8M |
| Cash & Short-term Investments | 30.0M | 36.1M | 23.6M | 29.5M | 21.4M | 11.0M | 33.9M | 41.5M | 43.2M | 53.1M | 27.9M |
| Total Debt | - | - | - | 7.49M | 1.74M | 1.39M | 846K | 6.35M | 6.93M | 8.15M | 8.31M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -16.4M | -16.5M | -12.2M | 8.29M | -6.90M | -8.92M | -11.9M | -10.5M | -13.6M | -14.5M | -31.2M |
| Capital Expenditure | 701K | 1.08M | 534K | 792K | 923K | 489K | 555K | 6.46M | 6.27M | 5.51M | 4.92M |
| Free Cash Flow | -17.1M | -17.5M | -12.7M | 7.50M | -7.82M | -9.41M | -12.4M | -16.9M | -19.9M | -20.0M | -36.1M |
| Ratios | |||||||||||
| ROE | -243.1% | -230.2% | -11.8% | 32.7% | -126.5% | - | -179.6% | -21.3% | -97.0% | -54.7% | -68.5% |
| ROA | -52.8% | -50.2% | -3.0% | 12.2% | -29.6% | -68.6% | -39.2% | -10.1% | -41.1% | -27.7% | -33.2% |
| Net Profit Margin | -1,212.1% | -887.4% | -31.1% | 15.6% | -42.3% | -57.0% | -74.0% | -35.9% | -149.5% | -140.8% | -200.6% |
| Debt to Equity | - | - | - | 0.49x | 0.24x | - | 0.08x | 0.20x | 0.22x | 0.19x | 0.26x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Mediwound Ltd dividends
Mediwound Ltd has not paid dividends in the last 9 fiscal years.
Last stock split: 1:7 on Dec 20, 2022.
Who owns Mediwound Ltd
- Insiders 15.91%
- Institutions 51.62%
- Public & others 32.48%
- Shares outstanding 14.4M
- Free float 8.87M
Top funds holding MDWD.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| iShares Russell 2000 ETF | 235K | 1.81% | 0.00% | Oct 2026 |
| T. Rowe Price New Horizons | 199K | 1.53% | -11.03% | Sep 2026 |
| ARK Israel Innovative Technology ETF | 167K | 1.28% | 0.00% | Oct 2026 |
| T. Rowe Price Integrated US Sm Gr Eq | 157K | 1.21% | 0.00% | Sep 2026 |
| Fidelity Small Cap Index | 110K | 0.85% | 0.00% | Aug 2026 |
| iShares Russell 2000 Growth ETF | 92.2K | 0.71% | -0.38% | Oct 2026 |
| Bridge Builder Small Cap Fund | 61.7K | 0.47% | 0.00% | Oct 2026 |
| T. Rowe Price Integrated US SMCC Eq I | 59.8K | 0.46% | +1.64% | Sep 2026 |
| Vanguard Russell 2000 ETF | 59.2K | 0.45% | +0.50% | Sep 2026 |
| iShares Micro-Cap ETF | 31.0K | 0.24% | 0.00% | Oct 2026 |
| Schwab Small Cap Index | 27.1K | 0.21% | +11.51% | Sep 2026 |
| iShares Russell 2000 Small-Cap Idx Instl | 21.1K | 0.16% | 0.00% | Sep 2026 |
| BrighthouseII T.Rowe Price Small Cp Gr A | 20.5K | 0.16% | 0.00% | Sep 2026 |
| Russell Inv US Small Cap Equity Y | 19.3K | 0.15% | 0.00% | Sep 2026 |
| Stt Strt SPDR® Russell2000 US SmCapETF | 17.9K | 0.14% | -5.83% | Oct 2026 |
| iShares Russell 3000 ETF | 13.5K | 0.10% | 0.00% | Oct 2026 |
| Transamerica T. Rowe Price Sm Cp VP Init | 12.3K | 0.09% | 0.00% | Sep 2026 |
| Nuveen Small Cap Blend Idx R6 | 10.8K | 0.08% | 0.00% | Sep 2026 |
| Vanguard Russell 2000 Growth ETF | 10.5K | 0.08% | -0.01% | Sep 2026 |
| Fidelity Small Cap Growth Index | 9.96K | 0.08% | +4.68% | Aug 2026 |
Top institutions holding MDWD.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Investors Finance Co PLC | 872K | 6.70% | 0.00% | Jun 2026 |
| Yelin Lapidot Holdings Management Ltd | 758K | 5.83% | -0.61% | Jun 2026 |
| Rosalind Advisors, Inc. | 749K | 5.76% | 0.00% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 641K | 4.93% | -9.69% | Jun 2026 |
| BlackRock Inc | 526K | 4.04% | +17.97% | Jun 2026 |
| Sphera Funds Management Ltd. | 273K | 2.10% | 0.00% | Jun 2026 |
| Silverberg Bernstein Capital Management LLC | 236K | 1.81% | +3.46% | Sep 2026 |
| State Street Corp | 169K | 1.30% | +17.32% | Jun 2026 |
| UBS Group AG | 156K | 1.20% | -2.42% | Jun 2026 |
| Geode Capital Management, LLC | 141K | 1.08% | +15.65% | Jun 2026 |
| Point72 Asset Management, L.P. | 129K | 0.99% | -26.35% | Jun 2026 |
| ARK Investment Management LLC | 127K | 0.97% | -2.60% | Jun 2026 |
| Northern Trust Corp | 112K | 0.86% | -7.87% | Jun 2026 |
| Dafna Capital Management LLC | 94.4K | 0.73% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 88.7K | 0.68% | +0.21% | Jun 2026 |
| Clal Insurance Enterprises Holdings Ltd | 71.0K | 0.55% | 0.00% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 70.1K | 0.54% | +21.89% | Jun 2026 |
| Sargent Investment Group, LLC | 62.5K | 0.48% | +5.04% | Jun 2026 |
| Citadel Advisors Llc | 58.5K | 0.45% | -1.26% | Jun 2026 |
| AQR Capital Management LLC | 50.4K | 0.39% | 0.00% | Jun 2026 |
Mediwound Ltd company profile
- Company name
- Mediwound Ltd
- Ticker
- MDWD.US
- ISIN
- IL0011316309
- Exchange
- USA Stocks
- Listed since
- Mar 20, 2014
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 121
- Fiscal year end
- December
- Address
- 42 Hayarkon Street, Yavne, Israel, 8122745
- Phone
- 972 7 797 14100
- Website
- mediwound.com
About Mediwound Ltd
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
Mediwound Ltd management
8- Mr. Ofer Gonen B.Sc.Chief Executive Officer · born 1973
- Ms. Hani LuxenburgChief Financial Officer · born 1974
- Dr. Shmulik Hess Ph.D.COO & Chief Commercial Officer · born 1974
- Mr. Yaron Meyer Adv.Executive VP, General Counsel & Corporate Secretary · born 1979
- Dr. Ety Klinger MBA, Ph.D.Chief Medical Officer · born 1962
- Dr. Liron GalVice President of Manufacturing Science & Technology
- Mr. Barry J. WolfensonExecutive Vice President of Strategy & Corporate Development · born 1967
- Dr. Robert J. Snyder CWS, D.P.M., F.A.C.F.A.S., FFPM, M.B.A., M.Sc.Senior Vice President of Global Medical Affairs · born 1951